Asset profile
cagrilintide/semaglutide · CagriSema
Peptide
Evidence outlook · lead readout
REDEFINE 2 (NCT05394519) · Overweight, Obesity, Type 2 Diabetes Mellitus
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
REDEFINE 2 (NCT05394519): This was a large, randomized, quadruple-blind, placebo-controlled trial in 1,200 patients using percentage body weight change, the standard efficacy measure for obesity treatment. CagriSema reduced body weight by 13.7% versus 3.4% on placebo, a 10.4-percentage-point difference (p<0.001), meeting the primary endpoint.
Also in development:Type 2 Diabetes · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
175 competitors in this universe: 58 direct rivals (same mechanism and indication), 1 same-class, 116 same-indication; 38 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Cagrilintide / Semaglutide (CagriSema): this drug | Phase 3 | Peptide | GLP-1 receptor, Amylin receptor | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor | ||
| Lixisenatide (Adlyxin / Lyxumia) | Approved | Peptide | GLP-1 receptor | ||
| Orforglipron (Foundayo) | Approved | Small molecule | GLP-1 receptor | ||
| Semaglutide (Wegovy / Ozempic / Rybelsus) | Approved | Peptide | GLP-1 receptor | ||
| Aleniglipron | Phase 3 | Small molecule | GLP-1 receptor | ||
| Amycretin | Phase 3 | Peptide | GLP-1 receptor, Amylin receptor | ||
| ASC30 | Phase 3 | Small molecule | GLP-1 receptor | ||
| AZD6234 | Phase 3 | Peptide | Amylin receptor | ||
| Cagrilintide | Phase 3 | Peptide | Amylin receptor, Amylin/calcitonin receptor (dual) | ||
| CJC-1134-PC | Phase 3 | Peptide | GLP-1 receptor | ||
| CX11 | Phase 3 | Small molecule | GLP-1 receptor | ||
| DA-302168S | Phase 3 | Small molecule | GLP-1 receptor | ||
| Ecnoglutide | Phase 3 | Peptide | GLP-1 receptor | ||
| Efpeglenatide | Phase 3 | Peptide | GLP-1 receptor |
…and 160 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
52 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (3)
March 2027 (1)
What to watch
June 2027 (1)
What to watch
October 2027 (1)
What to watch
2028 (1)
February 2028 (1)
What to watch
2029 (1)
September 2029 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.